All over the world, scientific discoveries and their medical potential are redefining the way society, politics and the medical community think about cannabis as a plant. In the past 5 years, more things have moved forward than in the 50 years before.
Amidst the ongoing legalization for medical and recreational purposes in North America and all around the world, Europe is following its own path. With more than 700 million inhabitants in continental Europe and 500 million within the EU, the market for cannabis is estimated to surpass 100 billion EUR by 2028.
Born out of Europe’s biggest market for Cannabis, Germany, Sanity Group specializes in Europe and its very distinct, localized markets, each with its own unique regulation, healthcare system and needs.
Together with our partners, we research and develop innovative cannabinoid-based pharmaceuticals and make them accessible and available to pharmacists, physicians and patients all over Europe.